F. Tas Et Al. , "Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma," BBA CLINICAL , vol.5, pp.166-169, 2016
Tas, F. Et Al. 2016. Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma. BBA CLINICAL , vol.5 , 166-169.
Tas, F., Bilgin, E., Karabulut, S., Erturk, K., & Duranyildiz, D., (2016). Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma. BBA CLINICAL , vol.5, 166-169.
Tas, Faruk Et Al. "Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma," BBA CLINICAL , vol.5, 166-169, 2016
Tas, Faruk Et Al. "Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma." BBA CLINICAL , vol.5, pp.166-169, 2016
Tas, F. Et Al. (2016) . "Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma." BBA CLINICAL , vol.5, pp.166-169.
@article{article, author={Faruk TAŞ Et Al. }, title={Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma}, journal={BBA CLINICAL}, year=2016, pages={166-169} }